October 2024

We are delighted to secure the support of Innovate UK to develop a novel platform for biological drug payload delivery. This propels our ambition to bring a pipeline of drugs to the clinic designed to be safer and more effective than the current standards of care for advanced cancers.

The STARLITE grant will enable Stratosvir to develop a complete immuno-oncology platform for discovery and delivery of novel proprietary therapeutic payloads, in collaboration with its German partner, in this bilateral arrangement between Innovate UK and ZIM (Zentrales Innovationsprogramm Mittelstand – Central Innovation Programme for SMEs.) Key outcomes will be vectorized antibody immunotherapies for treatment of advanced Prostate Cancer and other late-stage cancers. STARLITE will keep Stratosvir at the forefront of the fast-evolving viral immuno-oncology space.
The non-dilutive funding from Innovate UK augments recent investment by o2h Ventures, Cancer Research Horizons, Proven Connect (Prostate Cancer Research) and business angels.
Stratosvir was founded by Cancer Research Horizons and Deep Science Ventures and has operations at Stevenage Bioscience Catalyst and at the Sussex Drug Discovery Centre, University of Sussex, UK.

About Innovate UK
Innovate UK, part of UK Research and Innovation, is creating a better future by inspiring, involving and investing in businesses developing life-changing innovations. We provide targeted sectors with expertise, facilities and funding to test, demonstrate and evolve their ideas, driving UK productivity and economic growth. Join our network and communities of innovators to realise the potential of your ideas and accelerate business growth. Innovate UK: inspiring business innovation.